Early prediction of Glioma Recurrence to Radiotherapy by 31P MRS and 1H CEST MRI

Early prediction of Glioma Recurrence to Radiotherapy by 31P MRS and 1H CEST MRI - GRAPE

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON50558

Enrollment

Registered

2018-05-02

Start date

2019-03-26

Completion date

Unknown

Last updated

2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glioma Recurrence

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Main inclusion criteria for patients and healthy volunteers: • Minimum age 18 years Additional inclusion criteria for patients: • Recently diagnosed with GBM using biopsy • Scheduled for radiotherapy (no surgical resection possible or desirable)

Exclusion criteria

Exclusion criteria: Main exclusion criteria for patients and healthy volunteers: • Standard contraindications for 7T MRI scanning, including claustrophobia and active metallic implants (see standard 7T screening form for contraindications) • History of previously treated brain tumor • History of previous partial or total brain radiotherapy • Pregnancy Additional exclusion criteria for patients: • Altered consciousness prohibiting informed consent • Recurrent GBM

Design outcomes

Primary

Measure	Time frame
The study endpoint will be the amount of ATP, protein level and pH change in GBM before and after single dose and complete course of radiotherapy with respect to background levels. Reproducibility is assessed in controls assuming no alteration in metabolite levels. In addition, the correlation between Cx30 and ATP as well as Cx30 and pH and protein level will be assessed.	—

Countries

Netherlands

Outcome results